Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A cost-effectiveness analysis

Pancreas

Volumn 44, Issue 2, 2015, Pages 204-210

  Nicolás Pérez, David ^a   Castilla Rodríguez, Iván ^b,c,d   Gimeno García, Antonio Z ^a   Romero García, Rafael ^a   Núñez Díaz, Venancio ^a   Quintero, Enrique ^a,e  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b Canary Islands Foundation for Health and Research (FUNCIS)   (Spain)

^c Health Services Research on Chronic Patients Network (REDISSEC)   (Spain)

^d Center for Biomedical Research of the Canary Islands (CIBICAN)   (Spain)

^e UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Cost effectiveness; ERCP; NSAIDs; Pancreatitis; Stents

Indexed keywords

DICLOFENAC; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE PANCREATITIS; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONTE CARLO METHOD; PANCREATIC DUCT STENT; PRIORITY JOURNAL; ADVERSE EFFECTS; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; DECISION TREE; DRUG COST; ECONOMICS; HOSPITAL COST; MULTIMODALITY CANCER THERAPY; ODDS RATIO; PANCREATITIS; RECTAL DRUG ADMINISTRATION; RISK FACTOR; STATISTICAL MODEL; STENT; TIME; TREATMENT OUTCOME;

ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; DICLOFENAC; DRUG COSTS; FEMALE; HOSPITAL COSTS; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; ODDS RATIO; PANCREATITIS; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925867629     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000245     Document Type: Article

References (30)

1. Anderson MA, Fisher L, Jain R, et al. Complications of ERCP. Gastrointest Endosc. 2012; 75: 467-473.
2. Rochester J. Risks of endoscopic retrograde cholangiopancreatography and sphincterotomy. Tech Gastrointest Endosc. 2008; 10: 14-21.
3. Freeman ML. Complications of endoscopic retrograde cholangiopancreatography: avoidance and management. Gastrointest Endosc Clin N Am. 2012; 22: 567-586.
4. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001; 54: 425-434.
5. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996; 335: 909-918.
6. Woods KE, Willingham FF. Endoscopic retrograde cholangiopancreatography associated pancreatitis: a 15-year review. World J Gastrointest Endosc. 2010; 2: 165-178.
7. Dumonceau JM, Andriulli A, Deviere J, et al. European society of gastrointestinal endoscopy (ESGE) guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy. 2010; 42: 503-515.
8. Elmunzer BJ, Waljee AK, Elta GH, et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008; 57: 1262-1267.
9. Zheng MH, Xia HH, Chen YP. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. Gut. 2008; 57: 1632-1633.
10. Mazaki T, Mado K, Masuda H, et al. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. J Gastroenterol. 2014; 48: 343-355.
11. Mazaki T, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy. 2010; 42: 842-853.
12. Choudhary A, Bechtold ML, Arif M, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: ameta-analysis and systematic review. Gastrointest Endosc. 2011; 73: 275-282.
13. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012; 366: 1414-1422.
14. Khoshbaten M, Khorram H, Madad L, et al. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008; 23: e11-e16.
15. Montano Loza A, Rodriguez Lomeli X, Garcia Correa JE, et al. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Rev Esp Enferm Dig. 2007; 99: 330-336.
16. Murray B, Carter R, Imrie C, et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003; 124: 1786-1791.
17. Sotoudehmanesh R, Khatibian M, Kolahdoozan S, et al. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007; 102: 978-983.
18. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991; 37: 383-393.
19. Das A, Singh P, Sivak MV Jr, et al. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis. Gastrointest Endosc. 2007; 65: 960-968.
20. Bumbasirevic V, Radenkovic D, Jankovic Z, et al. Severe acute pancreatitis: overall and early versus late mortality in intensive care units. Pancreas. 2009; 38: 122-125.
21. Akbar A, Abu Dayyeh BK, Baron TH, et al. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol. 2013; 11: 778-783.
22. Freeman ML. Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2007; 5: 1354-1365.
23. Testoni PA, Mariani A, Giussani A, et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol. 2010; 105: 1753-1761.
24. Otsuka T, Kawazoe S, Nakashita S, et al. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol. 2012; 47: 912-917.
25. Senol A, Saritas U, Demirkan H. Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol. 2009; 15: 3999-4004.
26. Krahn MD, Naglie G, Naimark D, et al. Primer on medical decision analysis: part 4-analyzing the model and interpreting the results. Med Decis Making. 1997; 17: 142-151.
27. Garcia-Cano Lizcano J, Gonzalez Martin JA, Morillas Arino J, et al. Complications of endoscopic retrograde cholangiopancreatography. A study in a small ERCP unit. Rev Esp Enferm Dig. 2004; 96: 163-173.
28. Glomsaker T, Hoff G, Kvaloy JT, et al. Patterns and predictive factors of complications after endoscopic retrograde cholangiopancreatography. Br J Surg. 2013; 100: 373-380.
29. Stromberg C, Arnelo U, Enochsson L, et al. Possible mortality reduction by endoscopic sphincterotomy during endoscopic retrograde cholangiopancreatography: a population-based case-control study. Surg Endosc. 2012; 26: 1369-1376.
30. Early DS, Ben-Menachem T, Decker GA, et al. Appropriate use of GI endoscopy. Gastrointest Endosc. 2012; 75: 1127-1131.